Cargando…
Neuroimaging-based biomarkers for treatment selection in major depressive disorder
The use of neuroimaging approaches to identify likely treatment outcomes in patients with major depressive disorder is developing rapidly. Emerging work suggests that resting state pretreatment metabolic activity in the fronto-insular cortex may distinguish between patients likely to respond to psyc...
Autores principales: | Dunlop, Boadie W., Mayberg, Helen S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Les Laboratoires Servier
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4336918/ https://www.ncbi.nlm.nih.gov/pubmed/25733953 |
Ejemplares similares
-
Neuroimaging Advances for Depression
por: Dunlop, Boadie W., et al.
Publicado: (2017) -
Treatment-Specific Hippocampal Subfield Volume Changes With Antidepressant Medication or Cognitive-Behavior Therapy in Treatment-Naive Depression
por: Tai, Hua-Hsin, et al.
Publicado: (2021) -
Performance of the Adult ADHD Self-Report Scale-v1.1 in Adults with Major Depressive Disorder
por: Dunlop, Boadie W., et al.
Publicado: (2018) -
Neuroimaging in anxiety disorders
por: Holzschneider, Kathrin, et al.
Publicado: (2011) -
Pilot Study of Metabolomic Clusters as State Markers of Major Depression and Outcomes to CBT Treatment
por: Bhattacharyya, Sudeepa, et al.
Publicado: (2019)